oregovomab
Phase 3- Indications
- Ovarian cancer
Company intelligence / Profile preview
OncoQuest Pharmaceuticals
Edmonton, Alberta, Canadaoncoquestinc.com ↗
- Ownership
- Private
- Employees
- ~30
- Development stage
- Phase 3
01
Overview
Positive Phase II results for oregovomab in combination with carboplatin-paclitaxel chemotherapy for ovarian cancer, showing significant improvement in progression-free survival (41.8 months vs 12.2 months) and overall survival compared to chemotherapy alone
- Therapeutic areas
- Oncology
- Modalities
- Monoclonal antibodiesImmunotherapiesImmunoglobulin E antibodies
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Dual Industrial Co. Ltd.OncoVent Co. Ltd.
Beyond the preview
Go deeper on OncoQuest Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoQuest Pharmaceuticals.